Literature DB >> 7605865

Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection.

M M Yousfi1, H M el-Zimaity, M T al-Assi, R A Cole, R M Genta, D Y Graham.   

Abstract

BACKGROUND: Successful treatment of Helicobacter pylori infection results in cure of peptic ulcer disease. Multi-drug regimens are needed to cure this infection. We studied the effectiveness and side effect profile of two antibiotics active against Helicobacter pylori, metronidazole and clarithromycin, combined with omeprazole.
METHODS: We evaluated a combination therapy for H. pylori infection consisting of metronidazole (500 mg b.d.), omeprazole (20 mg b.d.), and clarithromycin (250 mg b.d.) for 2 weeks, followed by ranitidine 300 mg daily for 4 weeks.
RESULTS: Thirty-three patients with documented H. pylori infection were studied. Twenty had previously failed antimicrobial therapy, including one with metronidazole-based triple therapy and eight with macrolide-based therapy (five with clarithromycin-based therapy), and 11 with amoxycillin, tetracycline, and bismuth. H. pylori status was determined by histopathology using the Genta stain and by culture. H. pylori status was determined at entry and 4 weeks after completing antimicrobial therapy. The H. pylori infection was cured in 88% (95% CI = 72%-96%) including 90% of those who had failed previous anti-H. pylori therapies. Mild side effects were reported by 18%.
CONCLUSION: We conclude that the combination of metronidazole, omeprazole and clarithromycin is an effective treatment for H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605865     DOI: 10.1111/j.1365-2036.1995.tb00374.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.

Authors:  D J Kearney; A Brousal
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

Review 2.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 4.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

5.  Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure.

Authors:  M Matsuoka; Y Yoshida; K Hayakawa; S Fukuchi; K Sugano
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

6.  Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.

Authors:  M P Dore; G Leandro; G Realdi; A R Sepulveda; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

Review 7.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

8.  Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Authors:  M J Buckley; H X Xia; D M Hyde; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 9.  Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.

Authors:  F Mégraud; H P Doermann
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

10.  Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.

Authors:  P J Jenks; A Labigne; R L Ferrero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.